Co-Diagnostics
CODX | NASDAQ
$0.47
-$0.08 (-14.12%)
At close: Oct 27, 2026, 4:00 PM ET
Co-Diagnostics Company Profile
Company profile explainedCompany Profile
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Key Executives
| Name | Position |
|---|---|
| Dwight H. Egan | Chairman, CEO & President |
| Brian L. Brown | Chief Financial Officer & Company Secretary |
| Christopher Thurston | Chief Technology Officer |
| David Nielsen | Chief Operating Officer |
| Andrew Benson | Head of Investor Relations |
| Dan Bohrer | Executive VP of Finance & Accounting and Principal Financial & Accounting Officer |
| Mayuranki Almaula | Senior Vice President of Overseas Operations & Strategic Alliances |
| Richard David Abbott | President |
| Seth Egan | Chief Commercialization Officer & Strategy Officer |
| Wesley C. Lindsey | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 25, 2026 | 8-K | Current Report |
| Sep 21, 2026 | PRE 14A | Filing |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 16, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 3 | Filing |
| Sep 04, 2026 | 8-K | Current Report |
| Sep 04, 2026 | DEFA14A | Filing |
| Sep 04, 2026 | 8-K | Current Report |
| Sep 01, 2026 | EFFECT | Filing |
Co-Diagnostics
| Country | United States |
| IPO Date | Jul 12, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Dwight Egan |
Contact Details
2401 S. Foothill Dr. Salt Lake City,
Utah 84109 United States
Stock Details
| Ticker Symbol | CODX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001692415 |
| CUSIP Number | 189763204 |
| ISIN Number | US1897632048 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove CODX